title: The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience.
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Philip A
authors.initials: PA
authors.lastname: Thompson
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Uri
authors.initials: U
authors.lastname: Rozovski
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Keating
authors.affiliation: Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Francesco
authors.initials: F
authors.lastname: Stingo
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Susan C
authors.initials: SC
authors.lastname: Smith
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: William G
authors.initials: WG
authors.lastname: Wierda
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Falchi
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Susan M
authors.initials: SM
authors.lastname: O'Brien
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Zeev
authors.initials: Z
authors.lastname: Estrov
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Jan A
authors.initials: JA
authors.lastname: Burger
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ferrajoli
keywords: CD20 monoclonal antibodies; chronic lymphocytic leukaemia; lenalidomide; relapsed/refractory
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4650-7
references.pmid: 18628480
references.citation: J Clin Oncol. 2006 Dec 1;24(34):5343-9
references.pmid: 17088571
references.citation: Blood. 2008 Jun 1;111(11):5291-7
references.pmid: 18334676
references.citation: Blood. 2011 Sep 29;118(13):3489-98
references.pmid: 21725050
references.citation: J Clin Oncol. 2013 Feb 10;31(5):584-91
references.pmid: 23270003
references.citation: N Engl J Med. 2014 Mar 20;370(12):1101-10
references.pmid: 24401022
references.citation: J Clin Oncol. 2011 Mar 20;29(9):1175-81
references.pmid: 21189385
references.citation: Cancer Cell. 2012 Jun 12;21(6):723-37
references.pmid: 22698399
references.citation: Blood. 2013 Aug 1;122(5):734-7
references.pmid: 23801633